Noopept: The Peptide-Derived Nootropic Explained

Nootropic Peptides

1,000x more potent

Noopept is reported to be roughly 1,000 times more potent by weight than piracetam, the original racetam nootropic, though this comparison reflects dose rather than efficacy.

Ostrovskaya et al., J Psychopharmacol, 2007

Ostrovskaya et al., J Psychopharmacol, 2007

View as image

Noopept (GVS-111, omberacetam) occupies an unusual position in the peptide landscape. It is derived from a dipeptide (cycloprolylglycine) and was designed as a peptide-based nootropic, but its chemical modifications, an N-phenylacetyl group and a C-terminal ethyl ester, make it technically a small molecule rather than a peptide. That distinction matters because it gives noopept something almost no peptide drug has: oral bioavailability. Unlike cerebrolysin, which requires injection, or Semax, which requires intranasal delivery, noopept can be swallowed and absorbed from the gut, reaching the brain at active concentrations. Developed at the Zakusov Research Institute of Pharmacology in Moscow, noopept has been approved as a prescription nootropic in Russia since 1996 and is widely available as a research compound globally. Its mechanism centers on upregulation of neurotrophic factors in the hippocampus, making it a bridge between the nootropic peptide space and classical small-molecule pharmacology.

Why Noopept Is Not a Peptide

A peptide is a chain of amino acids connected by peptide bonds. Noopept contains only two amino acid residues (proline and glycine), placing it at the extreme lower end of peptide chemistry, a dipeptide. But two modifications remove it from the peptide category:

The N-terminal phenylacetyl group replaces the free amino group that dipeptides normally carry. This protects the molecule from aminopeptidase cleavage and changes its receptor interaction profile.

The C-terminal ethyl ester replaces the free carboxyl group. This modification is the key to oral bioavailability: it increases lipophilicity, allowing the molecule to cross cell membranes and the blood-brain barrier. Once in the brain, esterases cleave the ethyl group, releasing the active dipeptide cycloprolylglycine (cPG).

Cycloprolylglycine is the true active moiety. It is an endogenous dipeptide found naturally in the brain, where it modulates AMPA-type glutamate receptors. AMPA receptors mediate fast excitatory synaptic transmission and are essential for long-term potentiation (LTP), the cellular mechanism of learning and memory. By increasing cycloprolylglycine concentrations in the brain, noopept amplifies a naturally occurring modulatory signal rather than introducing a foreign one. This prodrug strategy, a modified peptide that delivers an endogenous active metabolite, is why noopept is categorized with peptide-derived drugs even though its pharmacology is that of a small molecule.

Neurotrophic Effects: NGF and BDNF

The most replicated finding in noopept research is its effect on neurotrophic factor expression. Gudasheva et al. (2008) demonstrated that noopept administration to rats increased mRNA expression of both nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) in the hippocampus. The time course was dose-schedule dependent: acute administration increased both NGF and BDNF mRNA in the hippocampus, while chronic 28-day dosing specifically increased BDNF mRNA in both the hippocampus and hypothalamus, with a different pattern for NGF.

This neurotrophic upregulation connects noopept to the broader neurotrophic peptide field. BDNF and NGF are the primary peptide growth factors that maintain hippocampal neuronal health, support synaptic plasticity, and protect against neurodegeneration. The finding that a small molecule can increase their expression orally is pharmacologically interesting, even though the magnitude and clinical relevance of this increase in humans remains unestablished.

Ostrovskaya et al. (2007) tested noopept in olfactory bulbectomized mice, an animal model of neurodegeneration that produces spatial memory deficits, neuroinflammation, and cholinergic dysfunction resembling aspects of Alzheimer's disease.^[1] Noopept restored spatial memory performance in the Morris water maze, and this behavioral improvement was accompanied by increased NGF expression in the hippocampus. The study also showed that noopept reduced markers of oxidative stress and neuroinflammation, suggesting that its neuroprotective effects extend beyond neurotrophic factor modulation.

Additional Mechanisms

AMPA Receptor Modulation

Cycloprolylglycine, noopept's active metabolite, acts as a positive modulator of AMPA receptors. AMPA receptor potentiation enhances fast glutamatergic transmission without the excitotoxicity risk of direct glutamate agonism. This mechanism overlaps with the ampakine class of nootropics and may explain noopept's acute cognitive effects (within hours of dosing, before neurotrophic gene expression changes could take effect).

HIF-1 Activation

Noopept increases the DNA-binding activity of hypoxia-inducible factor 1 (HIF-1), a transcription factor that drives adaptive responses to low oxygen. In the brain, HIF-1 activation promotes erythropoietin expression, angiogenesis, and glucose transporter upregulation. This pathway may contribute to noopept's neuroprotective effects in ischemic or hypoxic conditions.

Stress Kinase Inhibition

Noopept has been shown to decrease the activity of stress-activated protein kinases (JNK, p38 MAPK) in neuronal cells. These kinases are activated by oxidative stress, neuroinflammation, and excitotoxicity, all of which contribute to neuronal death in neurodegenerative diseases. By reducing stress kinase activity while increasing neurotrophic factor expression, noopept creates a dual protective effect: less death signaling and more survival signaling simultaneously.

How Noopept Compares to Related Compounds

vs. Piracetam

Noopept was developed as a more potent successor to piracetam, the original racetam nootropic. The reported 1,000-fold potency difference refers to effective dose (noopept at 10-30 mg vs piracetam at 2,400-4,800 mg), not to a specific bioassay comparison. Piracetam's mechanism involves broad modulation of membrane fluidity and neurotransmitter systems. Noopept's mechanism is more specific: AMPA receptor modulation via cycloprolylglycine, plus neurotrophic factor upregulation. Whether the more specific mechanism produces clinically superior cognitive enhancement has not been tested in a head-to-head human trial.

vs. Semax

Semax is a synthetic ACTH(4-10) analog that also increases BDNF expression and has neuroprotective properties. The key difference is delivery: Semax is a true peptide (7 amino acids) that requires intranasal administration because it cannot survive oral delivery. Semax et al. (2025) showed that Semax targets the mu-opioid receptor gene Oprm1 to promote lysosomal membrane stabilization after spinal cord injury, demonstrating mechanisms beyond neurotrophic factor modulation.^[5] Inozemtseva et al. (2024) compared Semax with Melanotan I for antidepressant and antistress effects, finding that both ACTH-derived peptides reduced stress-related behavioral deficits through distinct receptor pathways.^[4]

Radchenko et al. (2025) reviewed Semax's potential for Alzheimer's disease, noting its ability to modulate cholinergic neurotransmission and neuroinflammatory pathways in addition to BDNF upregulation.^[3]

vs. Cortexin

Cortexin is a brain-derived peptide extract (similar to cerebrolysin but from bovine brain cortex) used clinically in Russia. Kurkin et al. (2021) compared the neuroprotective action of cortexin, cerebrolysin, and actovegin in brain ischemia models.^[2] Cortexin and cerebrolysin both showed neuroprotective effects, though through different mechanisms. Unlike noopept, cortexin is a complex peptide mixture that requires intramuscular injection and contains dozens of uncharacterized peptide fragments.

Pharmacokinetics and Dosing

Noopept's pharmacokinetic profile distinguishes it from both true peptides and conventional racetams. After oral administration, noopept is rapidly absorbed from the gastrointestinal tract. Peak plasma concentrations occur within 15-20 minutes. The compound crosses the blood-brain barrier with measurable brain concentrations achieved within 25 minutes of oral dosing, based on preclinical data in rodents.

In the brain, esterases rapidly convert noopept to its active metabolite cycloprolylglycine. The parent compound's half-life is short (approximately 15-20 minutes), but the pharmacological effect persists longer because cycloprolylglycine has a longer residence time and because the neurotrophic gene expression changes initiated by noopept unfold over hours to days.

The standard dosing range established in Russian clinical practice is 10-30 mg per day, typically divided into two or three doses. This dose range represents one of the lowest in the nootropic category: piracetam is dosed at 2,400-4,800 mg, aniracetam at 750-1,500 mg, and phenylpiracetam at 100-200 mg. The low dose is consistent with noopept's high receptor-level potency but does not inherently mean greater clinical efficacy, since potency (the dose required for a given receptor effect) and efficacy (the maximum clinical benefit achievable) are independent pharmacological properties.

Noopept is typically taken in 8-12 week cycles in Russian clinical practice, though the rationale for cycling (versus continuous dosing) is empirical rather than based on formal tolerance or tachyphylaxis studies. Whether the neurotrophic factor upregulation observed in 28-day rodent studies continues, plateaus, or reverses with longer administration is unknown.

The Regulatory Landscape

Noopept is approved as a prescription medication in Russia (marketed as Noopept tablets, 10 mg) for cognitive impairment associated with cerebrovascular disease and organic brain syndromes. It is classified as a nootropic and neuroprotective agent. Russian clinical guidelines include it among options for mild cognitive impairment, though it is not a first-line treatment for any specific diagnosis.

In the United States and European Union, noopept has no regulatory approval. It is not classified as a controlled substance in most Western jurisdictions, which means it is available for purchase as a research chemical or, in some markets, as a dietary supplement. This regulatory ambiguity creates a situation where millions of people use noopept without clinical oversight, based on preclinical data and anecdotal reports rather than evidence from rigorous clinical trials.

The path to Western regulatory approval would require IND-enabling toxicology studies, Phase 1 dose-finding in healthy volunteers, Phase 2 efficacy trials in a defined patient population, and Phase 3 confirmatory trials. No entity has initiated this process. The compound's patent situation (original Russian patents have expired) reduces commercial incentive for the multi-hundred-million-dollar investment that Western regulatory approval requires.

The Evidence Gap

Noopept's research base has a characteristic shape: strong preclinical data from Russian laboratories, limited clinical data from Russian clinical practice, and essentially no independent Western clinical trials.

The preclinical evidence supports several conclusions: noopept crosses the blood-brain barrier after oral administration, increases neurotrophic factor expression in the hippocampus, restores cognitive function in animal models of neurodegeneration, reduces oxidative stress and neuroinflammation, and modulates AMPA receptor function through its active metabolite cycloprolylglycine.

What is missing:

No large placebo-controlled RCT in English-language journals. Russian clinical data reports cognitive improvement in patients with mild cognitive impairment and cerebrovascular disease, but these studies are typically small, lack rigorous blinding, and are published in Russian-language journals that are difficult to evaluate for methodological quality.

No dose-response data in healthy humans. The 10-30 mg dosing range used in clinical practice was established empirically. Systematic dose-finding studies with validated cognitive endpoints in healthy volunteers have not been published.

No long-term safety data. Noopept has been used clinically in Russia for decades, but formal pharmacovigilance data accessible to Western regulatory evaluation does not exist.

No comparison with established cognitive enhancers. Head-to-head trials against donepezil, memantine, or even piracetam would help establish noopept's clinical value but have not been conducted.

This evidence gap does not mean noopept is ineffective. It means the evidence base is insufficient to draw definitive conclusions by the standards of Western evidence-based medicine. The preclinical mechanism (neurotrophic factor upregulation, AMPA modulation, stress kinase inhibition) is biologically plausible and consistent across multiple animal models. Translation to clinical practice requires human data that does not yet exist at the required quality level.

The Bottom Line

Noopept (GVS-111) is a dipeptide-derived small molecule that achieves oral bioavailability through chemical modifications that true peptides cannot match. It acts as a prodrug of cycloprolylglycine, an endogenous AMPA receptor modulator, and increases BDNF and NGF expression in the hippocampus. Preclinical evidence from animal models of neurodegeneration shows cognitive restoration and neuroprotection. The compound bridges the peptide and small-molecule worlds, but its clinical evidence base consists primarily of small Russian studies without independent Western replication.

Frequently Asked Questions

Is noopept a peptide?

Noopept is derived from a dipeptide (proline-glycine) but is technically a small molecule due to its N-terminal phenylacetyl group and C-terminal ethyl ester modification. These changes give it oral bioavailability that true peptides lack. It is a prodrug that releases the endogenous dipeptide cycloprolylglycine in the brain.

What does noopept do to the brain?

Noopept increases expression of NGF and BDNF in the hippocampus, modulates AMPA-type glutamate receptors through its active metabolite cycloprolylglycine, reduces stress kinase activity, and activates HIF-1 transcription factor. In animal models, these effects translate to improved spatial memory and neuroprotection against oxidative and inflammatory damage.^[1]

Is noopept better than piracetam?

Noopept is active at doses approximately 1,000 times lower than piracetam by weight (10-30 mg vs 2,400-4,800 mg). This reflects dosing potency, not clinical superiority. No head-to-head clinical trial has compared the two compounds for cognitive outcomes. Noopept has a more defined mechanism (AMPA modulation, neurotrophic upregulation) than piracetam's broad membrane effects.

Is noopept FDA approved?

No. Noopept is not approved by the FDA or EMA. It has been approved as a prescription nootropic in Russia since 1996. In most Western countries, it is available as a research compound or dietary supplement, though regulatory classification varies by jurisdiction.

How does noopept compare to semax?

Both noopept and Semax increase BDNF expression and have neuroprotective properties. The key difference is that noopept is an orally bioavailable small molecule while Semax is a true peptide (7 amino acids) requiring intranasal delivery. Semax has a broader mechanism profile including opioid receptor modulation and cholinergic effects that noopept does not share.

What is cycloprolylglycine?

Cycloprolylglycine (cPG) is an endogenous cyclic dipeptide found naturally in the brain. It is the active metabolite of noopept, released when brain esterases cleave noopept's ethyl ester group. cPG acts as a positive modulator of AMPA-type glutamate receptors, enhancing fast excitatory synaptic transmission and supporting long-term potentiation (the cellular basis of learning and memory).